004 Steroids for Myeloma : The good, the bad and the ugly

Welcome to The Myeloma Minutes.   In this episode Jam & Sally explore the role of steroids in myeloma. A cornerstone of myeloma therapy for decades, these powerful drugs have impacted every patient treated for myeloma. They talk about their benefits, common side effects, and whether newer treatments could reduce the need for them in the future. You'll hear about the following: The important role of steroids as a treatment for myeloma. (the good !) The side effects (The bad , and sometimes the ugly !) Practical tips for dealing with some of these side effects Could newer treatments make steroids something we use much less in the future This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.